Application of cyclotrons in beam technologies

Ogloblin, A. A.; Унежев, В. Н.; Zagryadskiy, V. A.; Ryazanov, A. I.; Новиков, В. И.; Latushkin, S. T.; Malamut, T. Yu.

doi:10.1134/s1063778817050192

Cited by 1 publication

(2 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…With the use of a 3 He beam, the natural isotope composition of europium (47.81% 151 Eu, 52.19% 153 Eu) lends itself nicely to 151 Eu( 3 He,5n) 149 Tb and 153 Eu( 3 He, 7n) 149 Tb at medium-high beam energies (30–70 MeV). This method can efficiently produce 149 Tb, along with 152 Tb and 155 Tb, which could potentially be useful as match pairs for 149 Tb therapy. , …”

Section: Terbiummentioning

confidence: 99%

“…This method can efficiently produce 149 Tb, along with 152 Tb and 155 Tb, which could potentially be useful as match pairs for 149 Tb therapy. 459,460 A variety of heavy ion beams ( 10/11 B, 12 C, 14/15 N, 16/18 O, and 19 F) can also be used to directly produce 149 Tb, typically via irradiation of early lanthanide targets. Unfortunately, coproduction of 149m Tb is common and rather detrimental, as it hinders 149g Tb production and has an extremely low probability of decaying to 149g Tb.…”

Section: Alternative Terbium-149 Productionmentioning

confidence: 99%

See 1 more Smart Citation

Radioactive Main Group and Rare Earth Metals for Imaging and Therapy

2018

View full text Add to dashboard Cite

Radiometals possess an exceptional breadth of decay properties and have been applied to medicine with great success for several decades. The majority of current clinical use involves diagnostic procedures, which use either positron-emission tomography (PET) or single-photon imaging to detect anatomic abnormalities that are difficult to visualize using conventional imaging techniques (e.g., MRI and X-ray). The potential of therapeutic radiometals has more recently been realized and relies on ionizing radiation to induce irreversible DNA damage, resulting in cell death. In both cases, radiopharmaceutical development has been largely geared toward the field of oncology; thus, selective tumor targeting is often essential for efficacious drug use. To this end, the rational design of fourcomponent radiopharmaceuticals has become popularized. This Review introduces fundamental concepts of drug design and applications, with particular emphasis on bifunctional chelators (BFCs), which ensure secure consolidation of the radiometal and targeting vector and are integral for optimal drug performance. Also presented are detailed accounts of production, chelation chemistry, and biological use of selected main group and rare earth radiometals.

show abstract

Section: Terbiummentioning

confidence: 99%